MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jgh.13656

Медицинская библиотека · Journal of gastroenterology and hepatology · 2017

6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients.

Meijer Berrie, Kreijne Joany E, van Moorsel Sofia A W, Derijks Luc J J, Bouma Gerd, Mulder Chris J J, Wong Dennis R, van der Woude C Janneke, van Bodegraven Adriaan A, de Boer Nanne K H

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIM: Thiopurines have a favorable benefit-risk ratio in the treatment of inflammatory bowel disease. A feared adverse event of thiopurine therapy is myelotoxicity, mostly occurring due to toxic concentrations of the pharmacologically active metabolites 6-thioguaninenucleotides. In oncology, myelosuppression has also been associated with elevated 6-methylmercaptopurine (6-MMP). In this case series, we provide a detailed overview of 6-MMP-induced myelotoxicity in inflammatory bowel disease patients.

METHODS

We retrospectively scrutinized pharmacological laboratory databases of five participating centers over a 5-year period. Patients with leukocytopenia at time of elevated 6-MMP levels (>5700 pmol/8 × 108 red blood cells) were included for detailed chart review.

RESULTS

In this case series, we describe demographic, clinical, and pharmacological aspects of 24 cases of 6-MMP-induced myelotoxicity on weight-based thiopurine therapy with a median steady-state 6-MMP level of 14 500 pmol/8 × 108 red blood cells (range 6600-48 000). All patients developed leukocytopenia (white blood cell count 2.7 ± 0.9 × 109 /L) after a median period of 11 weeks after initiation of thiopurine therapy (interquartile range 6-46 weeks). Eighteen patients (75%) developed concurrent anemia (median hemoglobin concentration 6.9 × 109 /L), and four patients developed concurrent thrombocytopenia (median platelet count 104 × 109 /L). Leukocytopenia resolved in 20 patients (83%) within 4 weeks upon altered thiopurine treatment regimen, and white blood cell count was increasing, but not yet normalized, in the remaining four patients.

CONCLUSION

We observed that thiopurine-induced myelotoxicity also occurs because of (extremely) high 6-MMP concentrations in patients with a skewed thiopurine metabolism. Continued treatment with adapted thiopurine therapy was successful in almost all patients.

Для цитирования: Meijer Berrie, Kreijne Joany E, van Moorsel Sofia A W, Derijks Luc J J, Bouma Gerd, Mulder Chris J J, Wong Dennis R, van der Woude C Janneke, van Bodegraven Adriaan A, de Boer Nanne K H. 6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients.. Journal of gastroenterology and hepatology. 2017. DOI: 10.1111/jgh.13656.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.